Biotech Values

[jbog]

Zip,

I'm beginning to think that the sales are Sanofi's to lose. In other words, it looks like the hospital groups would prefer to stay with the original Lovenox as long as the 'price is right'.

Eyeambill's post;

HealthTrust Pharmacy Group has received many questions from its membership regarding enoxaparin, the generic launch, and the future of this class of pharmaceuticals. Currently, HealthTrust has a sole award with Sanofi-Aventis for brand name Lovenox®. Sanofi-Aventis recently brought additional value to HealthTrust's existing contract for Lovenox®, thus bringing additional value to the membership. This change in contract terms and value has been reflected in a previous Pharmacy Response and on CatScanRX.

This statement leads me to believe that Sanofi engaged in this contract after M-enox was on the market. This leads me to believe that Sanofi is now making new long term deals which will go on for some time. Our original belief was that we'd have to wake for the old contracts to expire. HealthTrust supports around 1400 hospitals while VHA supports around VHA serves 1,400 not-for-profit hospitals and more than 24,000 non-acute care health care organizations nationwide.

I'm scratching my head on this one.